Sandbox Anshika Page
From Proteopedia
(Difference between revisions)
(New page: == Hsp90N–SNX-2112 Complex (PDB ID: 6LTK)== <Structure Section load='1stp' size='340' side='right' caption='Overall structure of Hsp90N bound to SNX-2112' scene=''> This page summarizes ...) |
|||
| Line 1: | Line 1: | ||
| - | == Hsp90N–SNX-2112 Complex (PDB ID: 6LTK)== | + | == Hsp90N–SNX-2112 Complex (PDB ID: 6LTK) == |
| - | <Structure Section load='1stp' size='340' side='right' caption=' | + | <Structure Section load='1stp' size='340' side='right' caption='Crystal structure of Hsp90N bound to the inhibitor SNX-2112' scene=''> |
| - | This page | + | This page describes the 3D structure and biological relevance of the human Hsp90 N-terminal domain (Hsp90N) in complex with the anticancer inhibitor SNX-2112. The structure was solved at 2.14 Å resolution (PDB ID: 6LTK) and provides detailed molecular insights into how SNX-2112 stabilizes within the ATP-binding pocket of Hsp90 to inhibit chaperone activity. |
| - | + | ||
| - | + | ||
| - | + | ||
== Structure == | == Structure == | ||
| - | The structure | + | The protein in this structure represents the **N-terminal ATP-binding domain of human Hsp90**, consisting of a compact α/β fold typical of GHKL ATPases. |
| - | + | SNX-2112 binds deeply within the **adenine-binding cleft**, forming hydrogen bonds with key residues such as **Asp93, Leu107, Phe138, Tyr139, and Met98**. | |
| - | + | These interactions mimic ATP and competitively block nucleotide binding. | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | <scene name=" | + | <scene name="6LTK_overall">Overall fold of Hsp90N with bound SNX-2112</scene> |
== Function == | == Function == | ||
| - | Hsp90 is an ATP-dependent molecular chaperone | + | Hsp90 is an essential **ATP-dependent molecular chaperone** responsible for folding, stabilizing, and activating hundreds of client proteins, including kinases, steroid hormone receptors, and oncogenic regulators. |
| - | The | + | |
| - | + | The N-terminal domain performs: | |
| + | * ATP binding and hydrolysis | ||
| + | * Conformational switching required for chaperone cycling | ||
| + | * Recruitment and regulation of client proteins | ||
| + | |||
| + | SNX-2112 inhibits this critical ATP-dependent function. | ||
== Disease relevance == | == Disease relevance == | ||
| - | Hsp90 is | + | Hsp90 is heavily upregulated in cancer, where it stabilizes oncogenic clients such as: |
| - | + | * **Akt** | |
| - | + | * **Raf-1** | |
| - | + | * **HER2** | |
| - | + | * **EGFR** | |
| - | + | ||
| + | By inhibiting Hsp90, SNX-2112 disrupts these signaling pathways—leading to **apoptosis, cell-cycle arrest, and reduced proliferation**, especially in **non-small cell lung cancer (NSCLC)** cell lines (A549, H1299). | ||
== Relevance == | == Relevance == | ||
| - | The 6LTK structure | + | Hsp90 inhibitors are important anticancer therapeutics. |
| - | + | The 6LTK structure aids in: | |
| - | + | * Understanding inhibitor binding specificity | |
| - | + | * Designing improved SNX-2112 analogs | |
| - | + | * Creating next-generation Hsp90-targeted drugs with reduced toxicity | |
== Structural highlights == | == Structural highlights == | ||
| - | + | * **Deep hydrophobic binding pocket** with aromatic stacking | |
| - | + | * **Hydrogen bonds** between inhibitor heterocycles and Asp93 | |
| - | + | * **π–π interactions** with Phe138 and Tyr139 | |
| - | + | * **Tight cavity occupancy**—explaining high binding affinity | |
| - | <scene name=" | + | <scene name="6LTK_binding_pocket">Close-up of the ATP-binding pocket with SNX-2112</scene> |
| + | |||
| + | == Key structural insights == | ||
| + | 1. SNX-2112 strongly mimics ATP’s adenine interactions → competitive inhibition. | ||
| + | 2. The inhibitor’s rigid aromatic scaffold fits precisely into the pocket → high potency. | ||
| + | 3. The structure explains why SNX-2112 has selectivity for Hsp90 over related GHKL ATPases. | ||
| + | 4. These atomic details provide a platform for structure-guided cancer drug development. | ||
== Images == | == Images == | ||
| - | + | (Add your uploaded PyMOL images here) | |
| - | + | ||
| - | + | ||
== 3D Scenes (interactive) == | == 3D Scenes (interactive) == | ||
| - | + | * [[#6LTK_overall|Overall Hsp90N–SNX-2112 complex]] | |
| - | + | * [[#6LTK_binding_pocket|Binding pocket close-up]] | |
| - | + | ||
| - | == Methods / Data | + | == Methods / Data sources == |
| - | + | * PDB ID: **6LTK** | |
| - | + | * Resolution: **2.14 Å** | |
| - | + | * Technique: **X-ray crystallography** | |
| - | + | * Expression system: **E. coli** | |
| - | + | * Software: Proteopedia, PyMOL, Jmol | |
== References == | == References == | ||
| - | <references/> | + | <references> |
| + | <ref>Chen W. et al., Complex Crystal Structure Determination and In Vitro Anti-Non-Small Cell Lung Cancer Activity of Hsp90N Inhibitor SNX-2112. Frontiers in Molecular Biology, 2021. DOI: 10.3389/fmolb.2021.670964.</ref> | ||
| + | <ref>PDB entry 6LTK: www.rcsb.org</ref> | ||
| + | </references> | ||
== PyMOL Scripts == | == PyMOL Scripts == | ||
| - | '''1. | + | '''1. Overall structure''' |
<pre> | <pre> | ||
fetch 6ltk, async=0 | fetch 6ltk, async=0 | ||
hide everything | hide everything | ||
| - | show cartoon, | + | show cartoon, chain A |
| - | color | + | color lightblue, chain A |
| - | show sticks, | + | show sticks, resn SNX |
| - | color yellow, | + | color yellow, resn SNX |
| - | + | bg white | |
</pre> | </pre> | ||
'''2. Binding pocket close-up''' | '''2. Binding pocket close-up''' | ||
<pre> | <pre> | ||
| - | fetch 6ltk | + | fetch 6ltk, async=0 |
| - | select pocket, byres | + | hide everything |
| - | show | + | show cartoon, chain A |
| - | + | zoom resn SNX | |
| - | + | show sticks, resn SNX | |
| - | + | select pocket, byres (resn SNX around 4) | |
| + | show sticks, pocket | ||
| + | util.cbc pocket | ||
| + | bg white | ||
</pre> | </pre> | ||
| - | + | </StructureSection> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | </ | + | |
Current revision
Hsp90N–SNX-2112 Complex (PDB ID: 6LTK)
| |||||||||||
